Donald Bobo, Jr. Sells 11,386 Shares of Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 11,386 shares of the stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $83.76, for a total value of $953,691.36. Following the sale, the vice president directly owned 38,970 shares in the company, valued at $3,264,127.20. This trade represents a 22.61% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Edwards Lifesciences Stock Down 1.4%

EW stock opened at $83.06 on Friday. The stock has a 50-day simple moving average of $81.62 and a two-hundred day simple moving average of $79.03. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89. The firm has a market capitalization of $48.20 billion, a PE ratio of 35.80, a PEG ratio of 3.73 and a beta of 0.97. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. Edwards Lifesciences’s revenue was up 14.7% compared to the same quarter last year. During the same period last year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on EW shares. The Goldman Sachs Group set a $104.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Friday, October 31st. Royal Bank Of Canada upped their price objective on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Raymond James Financial upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price for the company in a research report on Monday, November 3rd. Citigroup reissued a “buy” rating and issued a $101.00 price target (up previously from $96.00) on shares of Edwards Lifesciences in a report on Thursday. Finally, Barclays restated an “overweight” rating and set a $103.00 price objective (up previously from $99.00) on shares of Edwards Lifesciences in a research report on Monday, December 8th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.30.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors have recently made changes to their positions in the business. JPL Wealth Management LLC purchased a new position in Edwards Lifesciences in the 3rd quarter worth $25,000. Quantbot Technologies LP purchased a new position in shares of Edwards Lifesciences in the first quarter worth about $26,000. SouthState Corp bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $27,000. Rosenberg Matthew Hamilton purchased a new stake in Edwards Lifesciences during the 2nd quarter valued at about $28,000. Finally, True Wealth Design LLC grew its position in Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after acquiring an additional 259 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.